Compare LGCB & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGCB | AIMD |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | Japan | United States |
| Employees | N/A | 44 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 9.8M |
| IPO Year | 2023 | N/A |
| Metric | LGCB | AIMD |
|---|---|---|
| Price | $1.49 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.0K | ★ 26.9K |
| Earning Date | 01-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.44 |
| 52 Week High | $3.10 | $4.50 |
| Indicator | LGCB | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 46.00 |
| Support Level | $1.43 | $1.33 |
| Resistance Level | $2.23 | $1.73 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 45.71 | 37.14 |
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.